TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05652686: A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Sponsor: Phanes Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 203 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$4,830,210

Rescue Site Savings

+$3,180,870

Unlock Full NCT05652686 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05652686 Rescue Dossier →